Godrej Agrovet had seen its earnings trajectory over FY20–24 slow down to 3.4% (EPS CAGR) vs. a robust 11.7% over FY14–19 amid Covid-19, volatile rainfall patterns and the larger base (due to Astec acquisition in 2015) driving slower growth. FY25 has seen a welcome return to growth, with a 16% YoY jump in Ebitda and a 19% jump in net earnings, driven by a sharp improvement in realisations/margins and marginal improvements in revenues from the Vegetable oil and Dairy segments.
NDTV Profit’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer NDTV Profit’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
The stronger performance over FY24–25 (16%/19% PAT growth seen in FY24/FY25) has not really reflected in Godrej Agrovet Ltd.’s stock price, with a ~11% dip in the stock price seen in the last 12 months.
At current levels, the stock trades at the lower end of the five-year PER and EV/Ebitda bands. Therefore, we see the robust 26% EPS growth over FY26–28E, coupled with the 600/700 bps boost in RoE/ROCE (FY28E vs FY26E) not fully reflecting in valuations – Applying the average 1 year forward PEG range over FY22-25 (1.3-1.6x) to FY27E/FY28E EPS delivers target price of Rs 843/1820 per share – implying 23-164% upside from current market price.
Our SoTP-based valuation, basis EV/Ebitda multiples of 12–16x based on FY28E for its different business segments and factoring in ~30% of HoldCo discount for Astec on current market price, delivers a target price of Rs 980, ~42% upside from CMP.
We initiate coverage on Gpdrej Agorvet with a Buy rating.
Key risks
Key upside risks:
Good monsoon; decline in competitive pressures; decrease in raw material prices; and higher number of new products.
Key downside risks:
Weaker-than-expected monsoon; steep increase in competitive pressures; increase in raw material prices; lower-than-expected offtake of new products; and an outbreak of disease could result in governmental restrictions on import/export/domestic sale of its fresh chicken or other products.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
RECOMMENDED FOR YOU
'Buy' Ather Energy Maintains HDFC Securities On Strong Growth Outlook; Stock Remains Top Pick


Godrej Agrovet Completes CEO Transition With Sunil Kataria Appointment


'Buy' Kalpataru Projects Shares Maintains Axis Securities On Growth Outlook — Check Target Price


Godrej Agrovet Q1 Results: Profit Up 19%
